Efficacy and tolerability of switching to telmisartan/amlodipine in patients with uncontrolled hypertension on RAS inhibitor monotherapy

Trial Profile

Efficacy and tolerability of switching to telmisartan/amlodipine in patients with uncontrolled hypertension on RAS inhibitor monotherapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2012

At a glance

  • Drugs Amlodipine/telmisartan (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms TEAMSTA Switch
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 01 May 2012 New trial record
    • 29 Apr 2012 Results presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension (ESH), according to a Boehringer Ingelheim media release.
    • 29 Apr 2012 Results published in a Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top